US5670488A
(en)
*
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
US20020164782A1
(en)
|
1999-02-10 |
2002-11-07 |
Gregory Richard J. |
Adenovirus vectors for gene therapy
|
US8153602B1
(en)
*
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5858784A
(en)
*
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
AU3467193A
(en)
*
|
1991-12-17 |
1993-07-19 |
Regents Of The University Of California, The |
Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR)
|
WO1994005782A1
(en)
*
|
1992-09-10 |
1994-03-17 |
Trustees Of Tufts College |
In vivo production of transgenic organ by introducing the transgene via lumen
|
EP1624068A1
(en)
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetic immunization with cationic lipids
|
US5688677A
(en)
*
|
1993-10-13 |
1997-11-18 |
Genzyme Corporation |
Deoxyribonucleic acids containing inactivated hormone responsive elements
|
US6887856B1
(en)
|
1993-10-15 |
2005-05-03 |
University Of Pittsburgh |
Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
|
WO1995010538A1
(en)
*
|
1993-10-15 |
1995-04-20 |
The University Of North Carolina At Chapel Hill |
Dna encoding the human p2u receptor and null cells expressing p2u receptors
|
FR2711523B1
(en)
|
1993-10-26 |
1996-02-16 |
Transgene Sa |
Process for the preparation of a viral aerosol.
|
US5614551A
(en)
*
|
1994-01-24 |
1997-03-25 |
The Johns Hopkins University |
Inhibitors of fatty acid synthesis as antimicrobial agents
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
AUPM747694A0
(en)
*
|
1994-08-16 |
1994-09-08 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids and peptides
|
FR2727679B1
(en)
*
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
|
US6383814B1
(en)
*
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
HU221204B1
(en)
*
|
1994-12-24 |
2002-08-28 |
Univ Cambridge Tech |
Use of nucleic acid for production of pharmaceuticals with tranfecting effect of nucleic acid on female mammals reproductive tract
|
US5795587A
(en)
*
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
FR2732895B1
(en)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTING AGENT, AS A VACCINE ADDITIVE, OR AS A MEDICINAL PRODUCT
|
US5935568A
(en)
*
|
1995-05-18 |
1999-08-10 |
National Jewish Medical & Research Center |
Gene therapy for effector cell regulation
|
US5756122A
(en)
*
|
1995-06-07 |
1998-05-26 |
Georgetown University |
Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
|
US5705385A
(en)
*
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6040296A
(en)
*
|
1995-06-07 |
2000-03-21 |
East Carolina University |
Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
|
AU771241B2
(en)
*
|
1995-06-07 |
2004-03-18 |
Tekmira Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
US5994315A
(en)
*
|
1995-06-07 |
1999-11-30 |
East Carolina University |
Low adenosine agent, composition, kit and method for treatment of airway disease
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US6025339A
(en)
*
|
1995-06-07 |
2000-02-15 |
East Carolina University |
Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
|
AU723163B2
(en)
*
|
1995-06-07 |
2000-08-17 |
Tekmira Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
AU7078396A
(en)
*
|
1995-09-27 |
1997-04-30 |
Regents Of The University Of California, The |
Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
|
US5869715A
(en)
*
|
1995-09-27 |
1999-02-09 |
The Reagents Of The University Of California |
Polyfunctional cationic cytofectins
|
US6121247A
(en)
*
|
1996-03-29 |
2000-09-19 |
The Johns Hopkins University |
Therapy for allergic diseases
|
US6156567A
(en)
*
|
1996-07-03 |
2000-12-05 |
Merial |
Truncated transcriptionally active cytomegalovirus promoters
|
WO1998010796A1
(en)
*
|
1996-09-12 |
1998-03-19 |
Genemedicine, Inc. |
Compositions and methods for pulmonary gene delivery
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
AU732447B2
(en)
|
1996-10-24 |
2001-04-26 |
Vanderbilt University |
Gene delivery and expression in areas inaccessible to direct protein delivery
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US5981575A
(en)
*
|
1996-11-15 |
1999-11-09 |
Johns Hopkins University, The |
Inhibition of fatty acid synthase as a means to reduce adipocyte mass
|
US6034072A
(en)
*
|
1997-02-10 |
2000-03-07 |
Genemedicine, Inc. |
IL-2 gene expression and delivery systems and uses
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5965542A
(en)
*
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
US20030229040A1
(en)
*
|
1997-03-21 |
2003-12-11 |
Georgetown University |
Cationic liposomal delivery system and therapeutic use thereof
|
US6559129B1
(en)
*
|
1997-03-21 |
2003-05-06 |
Georgetown University |
Cationic liposomal delivery system and therapeutic use thereof
|
US7262173B2
(en)
*
|
1997-03-21 |
2007-08-28 |
Georgetown University |
Chemosensitizing with liposomes containing oligonucleotides
|
US6126965A
(en)
*
|
1997-03-21 |
2000-10-03 |
Georgetown University School Of Medicine |
Liposomes containing oligonucleotides
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
US5958894A
(en)
*
|
1997-04-04 |
1999-09-28 |
Megabios Corporation |
Amphiphilic biguanide derivatives
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
US5952516A
(en)
*
|
1997-05-08 |
1999-09-14 |
Genzyme Corporation |
Cationic amphiphiles containing multiplesteroid lipophilic groups
|
US5942634A
(en)
*
|
1997-05-09 |
1999-08-24 |
Genzyme Corporation |
Cationic amphiphiles for cell transfections
|
CA2205076A1
(en)
|
1997-05-14 |
1998-11-14 |
Jim Hu |
Episomal expression cassettes for gene therapy
|
US20090239940A1
(en)
*
|
1997-07-22 |
2009-09-24 |
Del Monte Federica |
Treating heart failure and ventricular arrhythmias
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
EP1007673B1
(en)
|
1997-07-30 |
2008-12-17 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
US20050142126A1
(en)
*
|
1997-08-20 |
2005-06-30 |
Bernard Knoops |
Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
|
AU747438B2
(en)
|
1997-09-24 |
2002-05-16 |
Regents Of The University Of California, The |
Non-primate lentiviral vectors and packaging systems
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US20060165606A1
(en)
*
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6433040B1
(en)
*
|
1997-09-29 |
2002-08-13 |
Inhale Therapeutic Systems, Inc. |
Stabilized bioactive preparations and methods of use
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US7704962B1
(en)
*
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
US7157098B1
(en)
*
|
1998-01-06 |
2007-01-02 |
Roman Perez-Soler |
Gene therapy of tumors using non-viral delivery system
|
US6375980B1
(en)
*
|
1998-01-08 |
2002-04-23 |
Research Development Foundation |
Stabilization of lipid:DNA formulations during nebulization
|
TW520294B
(en)
*
|
1998-01-08 |
2003-02-11 |
Res Dev Foundation |
Stabilization of lipid: DNA formulations during nebulization
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
WO1999039741A2
(en)
|
1998-02-03 |
1999-08-12 |
Inex Pharmaceuticals Corporation |
Systemic delivery of serum stable plasmid lipid particles for cancer therapy
|
US6158431A
(en)
*
|
1998-02-13 |
2000-12-12 |
Tsi Incorporated |
Portable systems and methods for delivery of therapeutic material to the pulmonary system
|
US6221848B1
(en)
|
1998-05-11 |
2001-04-24 |
University Of Pittsburgh |
Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
|
AU757894B2
(en)
*
|
1998-05-21 |
2003-03-13 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the pulmonary delivery of nucleic acids
|
AU4007899A
(en)
*
|
1998-05-21 |
1999-12-06 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the pulmonary delivery of nucleic acids
|
US6693086B1
(en)
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
*
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
CN1317009A
(en)
*
|
1998-08-03 |
2001-10-10 |
东卡罗来纳大学 |
Low adenosine anti-sense oligonucleotide agent, composition, reagent kit and treatments
|
ES2281199T3
(en)
*
|
1998-11-12 |
2007-09-16 |
Transave, Inc. |
INHALATION SYSTEM
|
EP1839648A3
(en)
*
|
1998-11-12 |
2007-11-21 |
Transave, Inc. |
An inhalation system
|
EP1129064B1
(en)
|
1998-11-12 |
2008-01-09 |
Invitrogen Corporation |
Transfection reagents
|
US6855549B1
(en)
|
1998-11-23 |
2005-02-15 |
The University Of Iowa Research Foundation |
Methods and compositions for increasing the infectivity of gene transfer vectors
|
US6716810B1
(en)
*
|
1998-12-09 |
2004-04-06 |
Eleanor Roosevelt Institute |
Composition and method for regulation of body weight and associated conditions
|
WO2000050062A2
(en)
*
|
1999-02-24 |
2000-08-31 |
North Carolina State University |
Methods and compositions for altering mucus secretion
|
US7544772B2
(en)
*
|
2001-06-26 |
2009-06-09 |
Biomarck Pharmaceuticals, Ltd. |
Methods for regulating inflammatory mediators and peptides useful therein
|
US8501911B2
(en)
*
|
1999-02-24 |
2013-08-06 |
Biomarck Pharmaceuticals, Ltd |
Methods of reducing inflammation and mucus hypersecretion
|
CN1330513A
(en)
*
|
1999-04-06 |
2002-01-09 |
东卡罗来纳大学 |
Low adenosine anti-sense ligonucleotide, compositions, kit and method for treatment of airway disorders associate with bronchoconstriction, lung infflammations, allergy(ies) and surfactant deplection
|
JP4932086B2
(en)
*
|
1999-04-08 |
2012-05-16 |
インターセル ユーエスエイ、インコーポレイテッド |
Dry formulation for transcutaneous immunization
|
WO2001021837A1
(en)
*
|
1999-09-23 |
2001-03-29 |
The General Hospital Corporation |
Methods for potentiating antisense rna techniques
|
JP2003514855A
(en)
|
1999-10-13 |
2003-04-22 |
チャコン,マルコ,エー. |
Therapeutic intervention mimicking the effects of calorie restriction
|
US7115712B1
(en)
*
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
US7265088B1
(en)
|
2000-02-24 |
2007-09-04 |
North Carolina State University |
Method and compositions for altering mucus secretion
|
US7919469B2
(en)
|
2000-02-24 |
2011-04-05 |
North Carolina State University |
Methods and compositions for altering mucus secretion
|
CA2382133C
(en)
*
|
2000-05-10 |
2010-11-23 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US8404217B2
(en)
*
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US10293056B1
(en)
*
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US20020106368A1
(en)
*
|
2000-07-28 |
2002-08-08 |
Adrian Bot |
Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
|
DE60227157D1
(en)
*
|
2001-02-13 |
2008-07-31 |
Us Gov Sec Army |
IMPREGENTS FOR TRANSCUTANEOUS IMMUNIZATION AGAINST TRAVEL DIARRHOUS
|
US20030077829A1
(en)
*
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
AU2002256398A2
(en)
*
|
2001-04-30 |
2002-11-11 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
CA2449054C
(en)
*
|
2001-05-30 |
2011-01-04 |
The Scripps Research Institute |
Integrin targeting liposome for nucleic acid delivery
|
CA2456746A1
(en)
*
|
2001-08-20 |
2003-02-27 |
Transave, Inc. |
Method for treating lung cancers
|
US6793912B2
(en)
*
|
2001-08-20 |
2004-09-21 |
Transave Inc. |
Treatment of cancers by inhalation of stable platinum-containing formulations
|
WO2003037302A1
(en)
*
|
2001-10-30 |
2003-05-08 |
Windsor J Brian |
Method and system for the co-isolation of cognate dna, rna and protein sequences and method for screening co-isolates for defined activities
|
WO2004033620A2
(en)
|
2001-11-02 |
2004-04-22 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of rna interference
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
CN100384865C
(en)
*
|
2001-11-02 |
2008-04-30 |
嵌入治疗公司 |
Methods and composition for therapeutic use of RNA interference
|
AUPR894201A0
(en)
*
|
2001-11-19 |
2001-12-13 |
Women's And Children's Hospital |
Respiratory delivery for gene therapy and lentiviral delivery particle
|
ES2364636T3
(en)
|
2001-12-19 |
2011-09-08 |
Novartis Ag |
PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
|
AU2003230600B2
(en)
*
|
2002-03-05 |
2009-06-04 |
Transave, Inc. |
An inhalation system for prevention and treatment of intracellular infections
|
US20040110295A1
(en)
*
|
2002-05-28 |
2004-06-10 |
Maxygen, Inc., A Delaware Corporation |
Nucleic acid vectors
|
ES2354607T3
(en)
|
2002-06-28 |
2011-03-16 |
Protiva Biotherapeutics Inc. |
PROCEDURE AND APPLIANCE TO PRODUCE LIPOSOMES.
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
EP1545459A4
(en)
*
|
2002-08-02 |
2007-08-22 |
Transave Inc |
Platinum aggregates and process for producing the same
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
US7718189B2
(en)
*
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
KR101301653B1
(en)
*
|
2002-10-29 |
2013-08-30 |
트랜세이브, 인코포레이티드 |
Sustained release of antiinfectives
|
CN1708724A
(en)
*
|
2002-11-01 |
2005-12-14 |
科比恩公司 |
Multi-domain vertical alignment liquid crystal display
|
JP4838114B2
(en)
|
2003-02-04 |
2011-12-14 |
コーネル リサーチ ファウンデイション インコーポレイテッド |
How to prevent mitochondrial permeability transition
|
DK1625149T3
(en)
|
2003-05-01 |
2016-05-30 |
Cornell Res Foundation Inc |
METHOD AND carrying complexes for delivery of molecules to cells
|
WO2005020885A2
(en)
*
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
WO2005004913A1
(en)
*
|
2003-07-09 |
2005-01-20 |
Anges Mg, Inc. |
Pharmaceutical composition containing decoy and method of using the same
|
CN101291653B
(en)
*
|
2003-07-16 |
2012-06-27 |
普洛体维生物治疗公司 |
Lipid encapsulated interfering rna
|
US7291604B2
(en)
|
2003-09-03 |
2007-11-06 |
The General Hospital Corporation |
Methods of treating restenosis
|
CA2551022C
(en)
|
2003-09-15 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
DK1687066T3
(en)
|
2003-11-14 |
2012-11-26 |
Brigham & Womens Hospital |
Methods of Immunomodulation
|
KR20060123413A
(en)
*
|
2003-12-03 |
2006-12-01 |
추가이 세이야쿠 가부시키가이샤 |
EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN beta;-ACTIN PROMOTER
|
US8592368B2
(en)
*
|
2003-12-19 |
2013-11-26 |
University Of South Florida |
JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
|
AU2005206053A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Keio University |
Support accumulating in injured part in vascular channel
|
CA2971928C
(en)
|
2004-01-23 |
2019-01-08 |
Cornell Research Foundation, Inc. |
Methods for reducing oxidative damage
|
WO2005078848A2
(en)
*
|
2004-02-11 |
2005-08-25 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
WO2005089448A2
(en)
*
|
2004-03-18 |
2005-09-29 |
Transave, Inc. |
Administration of cisplatin by inhalation
|
EP1755623A4
(en)
*
|
2004-05-21 |
2007-10-17 |
Transave Inc |
Treatment of lung diseases and pre-lung disease conditions
|
WO2005121348A1
(en)
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
CA2569645C
(en)
|
2004-06-07 |
2014-10-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
CA2572439A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
WO2006007712A1
(en)
*
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
US20060045849A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Farhan Taghizadeh |
Method of customizing the fragrance of nasal medications
|
EP1811963A4
(en)
*
|
2004-11-08 |
2010-01-06 |
Transave Inc |
Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
|
AU2005306533B2
(en)
*
|
2004-11-17 |
2012-05-31 |
Arbutus Biopharma Corporation |
siRNA silencing of apolipoprotein B
|
NZ577196A
(en)
|
2005-01-20 |
2011-06-30 |
Biomarck Pharmaceuticals Ltd |
Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
|
WO2006091459A2
(en)
*
|
2005-02-24 |
2006-08-31 |
Joslin Diabetes Center, Inc. |
Compositions and methods for treating vascular permeability
|
EP1866414B9
(en)
|
2005-03-31 |
2012-10-03 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
UA95446C2
(en)
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Mutations in oas1 genes
|
US20070031342A1
(en)
*
|
2005-06-22 |
2007-02-08 |
Nektar Therapeutics |
Sustained release microparticles for pulmonary delivery
|
US20110178092A1
(en)
*
|
2005-06-22 |
2011-07-21 |
Akbar Ali |
HIV-1 Protease Inhibitors
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US7541340B2
(en)
*
|
2005-09-16 |
2009-06-02 |
Cornell Research Foundation, Inc. |
Methods for reducing CD36 expression
|
CA2627585A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Alnylam Pharmaceuticals, Inc. |
Rnai inhibition of influenza virus replication
|
CN101346393B
(en)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
Modified siRNA molecules and uses thereof
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
WO2007056264A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Transave, Inc. |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
EP3067047B1
(en)
|
2005-12-08 |
2022-04-20 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
JP2009525757A
(en)
|
2006-02-10 |
2009-07-16 |
ザ ユニバーシティ オブ シンシナティ |
Phosphatase inhibitor protein-1 as a regulator of cardiac function
|
KR100745833B1
(en)
|
2006-03-06 |
2007-08-02 |
고려대학교 산학협력단 |
Complex composition of cationic gold nanoparticles and dna for effective transfection
|
US7846908B2
(en)
*
|
2006-03-16 |
2010-12-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of TGF-beta and therapeutic uses thereof
|
US8968702B2
(en)
*
|
2006-03-30 |
2015-03-03 |
Duke University |
Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
|
WO2007124131A2
(en)
*
|
2006-04-20 |
2007-11-01 |
The University Of North Carolina At Chapel Hill |
Hybrid nanomaterials as multimodal imaging contrast agents
|
CA2652770A1
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
BRPI0714953A2
(en)
|
2006-07-26 |
2013-07-16 |
Biomarck Pharmaceuticals Ltd |
Methods to attenuate the release of inflammatory mediators and useful peptides in this regard
|
KR100825519B1
(en)
*
|
2007-01-05 |
2008-04-25 |
주식회사 바이오폴리메드 |
A chitosan based polymer conjugate and a method for producing the same
|
WO2008137717A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
WO2008144591A2
(en)
|
2007-05-16 |
2008-11-27 |
The Brigham And Women's Hospital, Inc. |
Treatment of synucleinopathies
|
CN101939019B
(en)
|
2008-02-07 |
2014-07-16 |
康奈尔大学 |
Methods for preventing or treating insulin resistance
|
US20110135571A1
(en)
*
|
2008-02-22 |
2011-06-09 |
Wenbin Lin |
Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
|
EP3243521B1
(en)
|
2008-02-26 |
2020-05-27 |
Cornell University |
A peptide for use for prevention and treatment of acute renal injury
|
BRPI0911332A2
(en)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
compositions and use of epas1 inhibitors
|
CA2758415C
(en)
|
2008-04-14 |
2019-06-04 |
The General Hospital Corporation |
Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
|
JP5475753B2
(en)
|
2008-04-15 |
2014-04-16 |
プロチバ バイオセラピューティクス インコーポレイティッド |
Lipid formulations for nucleic acid delivery
|
EP2294184A4
(en)
|
2008-06-30 |
2013-03-06 |
Mesoblast Inc |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
WO2010017094A2
(en)
|
2008-07-31 |
2010-02-11 |
The General Hospital Corporation |
CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
|
EP2743265B1
(en)
|
2008-10-09 |
2017-03-15 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
EP2361098B1
(en)
|
2008-10-31 |
2019-08-28 |
The General Hospital Corporation |
Compositions and methods for delivering a substance to a biological target
|
EP2344519B1
(en)
|
2008-11-07 |
2016-09-28 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
TW201031436A
(en)
*
|
2009-02-16 |
2010-09-01 |
Univ Nat Taiwan |
Pharmaceutical composition for inhalation delivery and fabrication method thereof
|
WO2010105096A2
(en)
|
2009-03-11 |
2010-09-16 |
University Of Massachusetts |
Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
|
WO2010120431A2
(en)
|
2009-03-20 |
2010-10-21 |
The General Hospital Corporation D/B/A Massachusetts General Hospital |
Methods for the prevention and treatment of burn injuries and secondary complications
|
JP2010251707A
(en)
*
|
2009-03-27 |
2010-11-04 |
Fujitsu Ltd |
Wiring board, and semiconductor device
|
EP2756845B1
(en)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
ES2613498T3
(en)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
New lipid formulations for the delivery of therapeutic agents to solid tumors
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
JP5909182B2
(en)
|
2009-08-12 |
2016-04-26 |
コーネル ユニヴァーシティー |
Methods for preventing or treating metabolic syndrome
|
HRP20231277T1
(en)
|
2009-08-24 |
2024-02-02 |
Stealth Biotherapeutics Inc. |
Peptide for use in preventing or treating macular degeneration
|
WO2011041385A2
(en)
|
2009-09-29 |
2011-04-07 |
Joslin Diabetes Center, Inc. |
Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
|
EP3603658A1
(en)
*
|
2009-10-05 |
2020-02-05 |
Cornell University |
Methods for the prevention or treatment of cardiac fibrosis
|
AU2010326132B9
(en)
|
2009-12-01 |
2014-10-02 |
Translate Bio, Inc. |
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
|
CN103830719A
(en)
|
2009-12-31 |
2014-06-04 |
康肽德生物医药技术有限公司 |
Methods for performing coronary artery bypass graft procedure
|
US20130195837A1
(en)
|
2009-12-31 |
2013-08-01 |
Stealth Peptides International, Inc. |
Methods for the prevention or treatment of vessel occlusion injury
|
CN102834408A
(en)
|
2010-01-25 |
2012-12-19 |
康奈尔大学 |
Aromatic-cationic peptides and uses of same
|
WO2011106525A2
(en)
|
2010-02-26 |
2011-09-01 |
The Brigham And Women's Hospital, Inc. |
Methods of treating cerebral amyloid angiopathy
|
EP3040080A1
(en)
|
2010-03-15 |
2016-07-06 |
Stealth Peptides International, Inc. |
Combination therapies using cyclosporine and aromatic cationic peptides
|
US20130078238A1
(en)
|
2010-04-29 |
2013-03-28 |
Hadasit Medical Research Services & Decvelopment Co. Ltd. |
Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy
|
WO2011139992A1
(en)
|
2010-05-03 |
2011-11-10 |
Stealth Peptides International, Inc. |
Aromatic-cationic peptides and uses of same
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
CN105879008A
(en)
|
2010-07-09 |
2016-08-24 |
康德生物医疗技术公司 |
Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
|
WO2012050673A1
(en)
|
2010-10-14 |
2012-04-19 |
Wisconsin Alumni Research Foundation |
Methods for the treatment of x-linked hypophosphatemia and related disorders
|
WO2012054718A2
(en)
|
2010-10-22 |
2012-04-26 |
The General Hospital Corporation |
Treating long qt syndrome
|
WO2012065182A2
(en)
|
2010-11-12 |
2012-05-18 |
University Of Massachusetts |
Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
|
EP2655409A4
(en)
|
2010-12-22 |
2015-07-01 |
Univ Leland Stanford Junior |
Superagonists and antagonists of interleukin-2
|
EP3108975A1
(en)
|
2011-03-24 |
2016-12-28 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
EP2691515A2
(en)
|
2011-03-31 |
2014-02-05 |
President and Fellows of Harvard College |
A unique population of regulatory t cells that regulate tissue regeneration and wound healing
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
EP3494974B1
(en)
|
2011-07-08 |
2023-10-18 |
The University of North Carolina at Chapel Hill |
Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
|
WO2013049697A1
(en)
|
2011-09-29 |
2013-04-04 |
Mayo Foundation For Medical Education And Research |
Aromatic-cationic peptides and methods for using same
|
GB201118704D0
(en)
*
|
2011-10-28 |
2011-12-14 |
Univ Oxford |
Cystic fibrosis treatment
|
JP2014533953A
(en)
|
2011-11-17 |
2014-12-18 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Therapeutic RNA switch compositions and methods of use
|
CA2858550A1
(en)
|
2011-12-09 |
2013-06-13 |
Stealth Peptides International, Inc. |
Aromatic-cationic peptides and uses of same
|
CA2865317A1
(en)
|
2012-02-22 |
2013-08-29 |
Stealth Peptides International, Inc. |
Methods and compositions for preventing or treating ophthalmic conditions
|
US10808008B2
(en)
|
2012-02-23 |
2020-10-20 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
US9603897B2
(en)
|
2012-03-12 |
2017-03-28 |
Massachusetts Institute Of Technology |
Methods for treating tissue damage associated with ischemia with apolipoprotein D
|
US9534059B2
(en)
|
2012-04-13 |
2017-01-03 |
Children's Medical Center Corporation |
TIKI inhibitors
|
CN104349783B
(en)
|
2012-05-21 |
2018-07-13 |
英斯麦德公司 |
The system for treating pulmonary infection
|
EP2858679B1
(en)
*
|
2012-06-08 |
2021-02-24 |
Translate Bio, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
CA2880643A1
(en)
|
2012-08-02 |
2014-02-06 |
Stealth Peptides International, Inc. |
Methods for treatment of atherosclerosis
|
WO2014025808A1
(en)
|
2012-08-06 |
2014-02-13 |
The General Hospital Corporation |
Curcumin analogs
|
CN112451486A
(en)
|
2012-09-04 |
2021-03-09 |
埃莱森制药有限责任公司 |
Prevention of pulmonary recurrence of cancer with cisplatin lipid complexes
|
EP2908839B1
(en)
|
2012-10-22 |
2019-08-21 |
Stealth Peptides International, Inc. |
Methods for reducing risks associated with heart failure and factors associated therewith
|
WO2014065860A1
(en)
|
2012-10-24 |
2014-05-01 |
The General Hospital Corporation |
Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
|
RU2675859C2
(en)
|
2012-11-29 |
2018-12-25 |
Инсмед Инкорпорейтед |
Stabilised vancomycin formulations
|
EP3287172A1
(en)
|
2012-12-06 |
2018-02-28 |
Stealth Peptides International, Inc. |
Combinations of peptide therapeutics and methods for using same
|
EP3789022A1
(en)
|
2012-12-27 |
2021-03-10 |
Massachusetts Eye & Ear Infirmary |
Treatment of rhinosinusitis with p-glycoprotein inhibitors
|
EP2943190B1
(en)
|
2013-01-11 |
2019-01-02 |
Massachusetts Eye & Ear Infirmary |
Cyp450 lipid metabolites reduce inflammation and angiogenesis
|
EP2769732A1
(en)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2851086A1
(en)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpins: methods of therapeutic ß-cell regeneration and function
|
US20160002316A1
(en)
|
2013-02-22 |
2016-01-07 |
Joslin Diabetes Center |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP3673913A1
(en)
|
2013-03-01 |
2020-07-01 |
Stealth Biotherapeutics Corp |
Methods for the treatment of mitochondrial disease
|
DK2961420T3
(en)
|
2013-03-01 |
2019-10-07 |
Stealth Biotherapeutics Corp |
METHODS AND COMPOSITIONS FOR PREVENTION OR TREATMENT OF BARTH SYNDROME
|
WO2014160221A1
(en)
|
2013-03-13 |
2014-10-02 |
The General Hospital Corporation |
Photoswitchable hdac inhibitors
|
WO2014159878A2
(en)
|
2013-03-13 |
2014-10-02 |
Regents Of The University Of California |
Intranasal administration of guanidinylated aminoglycosides
|
DK2970225T3
(en)
|
2013-03-14 |
2018-09-24 |
Onyx Therapeutics Inc |
DIPEPTIDE AND TRIPEPTIDE AS EPOXY-KETONE PROTEASE INHIBITORS
|
AR095426A1
(en)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
|
CA2904350A1
(en)
|
2013-03-15 |
2014-09-25 |
The General Hospital Corporation |
Glycine, mitochondrial one-carbon metabolism, and cancer
|
CA2912386A1
(en)
|
2013-05-14 |
2014-11-20 |
Stealth Biotherapeutics Corp |
Methods for the prevention or treatment of left ventricular remodeling
|
US9737525B2
(en)
|
2013-06-07 |
2017-08-22 |
The General Hospital Corporation |
Small molecule activators of NRF2 pathway
|
WO2014210062A1
(en)
|
2013-06-26 |
2014-12-31 |
Stealth Peptides International, Inc. |
Methods for the regulation of matrix metalloproteinase expression
|
WO2014209905A2
(en)
|
2013-06-26 |
2014-12-31 |
Stealth Peptides International, Inc. |
Methods and compositions for detecting and diagnosing diseases and conditions
|
CA2916486A1
(en)
|
2013-06-26 |
2015-01-22 |
Stealth Biotherapeutics Corp |
Methods and compositions comprising an aromatic peptide for regulating serca2a expression levels in myocardinal infarction
|
CA2916492A1
(en)
|
2013-06-27 |
2014-12-31 |
Stealth Biotherapeutics Corp |
Peptide therapeutics and methods for using same
|
US20160166633A1
(en)
|
2013-08-02 |
2016-06-16 |
Stealth Bio Therapeutics Corp |
Methods and compositions for the prevention and treatment of friedreich's ataxia
|
WO2015034996A1
(en)
|
2013-09-06 |
2015-03-12 |
The General Hospital Corporation |
Imaging brown adipose tissue with curcumin derivatives
|
US10781242B2
(en)
|
2013-09-24 |
2020-09-22 |
Medicenna Therapeutics Inc. |
Interleukin-2 fusion proteins and uses thereof
|
JP6590802B2
(en)
|
2013-11-06 |
2019-10-16 |
ザ ユニバーシティ オブ シカゴThe University Of Chicago |
Nanoscale transporter for delivery or co-delivery of chemotherapeutic drugs, nucleic acids and photosensitizers
|
CA2932408A1
(en)
|
2013-12-02 |
2015-06-11 |
Stealth Biotherapeutics Corp |
Compositions and methods for treating vitiligo
|
WO2015103643A2
(en)
|
2014-01-06 |
2015-07-09 |
The General Hospital Corporation |
Integrin antagonists
|
CA2943609A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
EP3134102B1
(en)
|
2014-04-24 |
2019-07-03 |
The Board of Trustees of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
PT3142643T
(en)
|
2014-05-15 |
2019-10-28 |
Insmed Inc |
Methods for treating pulmonary non-tuberculous mycobacterial infections
|
EP3143166A4
(en)
|
2014-05-16 |
2018-04-18 |
University of Massachusetts |
Treating chronic myelogenous leukemia (cml)
|
EP3501532A3
(en)
|
2014-05-28 |
2019-07-17 |
Stealth BioTherapeutics Corp |
Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
|
CA2950410A1
(en)
|
2014-05-28 |
2015-12-03 |
D. Travis Wilson |
Therapeutic compositions including therapeutic small molecules and uses thereof
|
EP3154694A1
(en)
|
2014-06-13 |
2017-04-19 |
Children's Medical Center Corporation |
Products and methods to isolate mitochondria
|
WO2015195737A1
(en)
|
2014-06-17 |
2015-12-23 |
Stealth Peptides International, Inc. |
Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
|
EP3169310A1
(en)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
US10179775B2
(en)
|
2014-08-11 |
2019-01-15 |
The General Hospital Corporation |
Cyclooctenes for bioorthogonol reactions
|
CN107106637B
(en)
|
2014-08-21 |
2021-06-25 |
康德生物医疗技术公司 |
Methods and compositions for disease prevention and treatment
|
JO3474B1
(en)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
|
WO2016061256A1
(en)
|
2014-10-14 |
2016-04-21 |
The University Of Chicago |
Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
|
US10806694B2
(en)
|
2014-10-14 |
2020-10-20 |
The University Of Chicago |
Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
|
EP3218373B1
(en)
|
2014-11-10 |
2020-07-22 |
Evrys Bio, LLC |
Anti-hcmv compositions and methods
|
WO2016077240A2
(en)
|
2014-11-10 |
2016-05-19 |
Forge Life Science, Llc |
Anti-hcmv compositions and methods
|
WO2016077382A2
(en)
|
2014-11-11 |
2016-05-19 |
Massachusetts Eye & Ear Infirmary |
Conjunctivitis vaccines
|
WO2016100401A1
(en)
|
2014-12-15 |
2016-06-23 |
Dicerna Pharmaceuticals, Inc. |
Ligand-modified double-stranded nucleic acids
|
CA2973585A1
(en)
|
2015-01-12 |
2016-07-21 |
Children's Medical Center Corporation |
Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
WO2016164642A1
(en)
|
2015-04-08 |
2016-10-13 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
US10967073B2
(en)
|
2015-05-07 |
2021-04-06 |
The Mclean Hospital Corporation |
Glucocerebrosidase gene therapy for Parkinson's disease
|
WO2016193945A2
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
EP3347377B1
(en)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
WO2017059338A1
(en)
|
2015-10-02 |
2017-04-06 |
Cornell University |
Enzyme-responsive peptide nanofiber compositions and uses thereof
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
US11001622B2
(en)
|
2015-11-19 |
2021-05-11 |
The Brigham And Women's Hospital, Inc. |
Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
|
JOP20200228A1
(en)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
Compositions and methods for decreasing tau expression
|
CA3010599A1
(en)
|
2016-01-06 |
2017-07-13 |
D. Travis Wilson |
Methods and compositions for the prevention and treatment of duchenne muscular dystrophy
|
WO2017123933A1
(en)
|
2016-01-15 |
2017-07-20 |
Massachusetts Eye And Ear Infirmary |
Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
|
WO2017147410A1
(en)
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
JP2019523217A
(en)
|
2016-05-19 |
2019-08-22 |
ステルス バイオセラピューティックス コープ |
Compositions and methods for prevention and treatment of mitochondrial myopathy
|
WO2017201528A1
(en)
|
2016-05-20 |
2017-11-23 |
The University Of Chicago |
Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
|
WO2017218355A1
(en)
|
2016-06-15 |
2017-12-21 |
Counterpoint Biomedica Llc |
Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
|
US10449230B2
(en)
|
2016-10-06 |
2019-10-22 |
The Regents Of The University Of California |
Polymyxin derived cell penetrating scaffolds
|
WO2018089688A1
(en)
|
2016-11-09 |
2018-05-17 |
Jinjun Shi |
Restoration of tumor suppression using mrna-based delivery system
|
CN109996809A
(en)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
Composition relevant to fusogenic protein MINION, method and therapeutical uses
|
HUE055417T2
(en)
|
2016-12-09 |
2021-11-29 |
Akston Biosciences Corp |
Insulin-fc fusions and methods of use
|
US20200054660A1
(en)
|
2016-12-09 |
2020-02-20 |
St. Jude Children's Research Hospital |
Dna methylation profiling for t-cell immunotherapy
|
US10913779B2
(en)
|
2017-01-25 |
2021-02-09 |
Counterpoint Biomedica Llc |
Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
|
JP6453507B2
(en)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Compound that inhibits MCL-1 protein
|
EP3641814A4
(en)
|
2017-06-19 |
2021-06-23 |
Medicenna Therapeutics Inc. |
Uses and methods for il-2 superagonists, agonists, and fusions thereof
|
CA3068010A1
(en)
|
2017-06-20 |
2018-12-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
|
WO2019006155A1
(en)
|
2017-06-28 |
2019-01-03 |
Children's Medical Center Corporation |
Promoting lung growth
|
KR20200032722A
(en)
|
2017-07-27 |
2020-03-26 |
노파르티스 아게 |
Partial cleavage resistance TREM2 variant
|
BR102017016440A2
(en)
*
|
2017-07-31 |
2019-03-19 |
Universidade Federal Do Rio Grande Do Sul |
COMPOSITION FOR CENTRAL NERVOUS SYSTEM GENE THERAPY, OBTAINING AND USE PROCESS
|
JP7364552B2
(en)
|
2017-08-02 |
2023-10-18 |
ザ ユニバーシティ オブ シカゴ |
Nanoscale metal-organic layers and metal-organic nanoplates for X-ray-induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
|
US11458139B2
(en)
|
2017-08-08 |
2022-10-04 |
Memorial Sloan Kettering Cancer Center |
Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor
|
US20210128702A1
(en)
|
2017-08-11 |
2021-05-06 |
Dana-Farber Cancer Institute, Inc. |
Use of a botulinum toxin agent for treating plasma cell disorders
|
EP3668968A1
(en)
|
2017-08-14 |
2020-06-24 |
Sanford Burnham Prebys Medical Discovery Institute |
Cardiogenic mesoderm formation regulators
|
EP3668878A1
(en)
|
2017-08-18 |
2020-06-24 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
EP3676270A1
(en)
|
2017-08-29 |
2020-07-08 |
Amgen Inc. |
Macrocyclic compounds that inhibit mcl-1 protein
|
WO2019046668A1
(en)
|
2017-08-31 |
2019-03-07 |
Kezar Life Sciences |
Amide substituted thiazoles as protein secretion inhibitors
|
EP3697783A4
(en)
|
2017-10-18 |
2023-04-26 |
Evrys Bio, LLC |
Broad spectrum antiviral compositions and methods
|
WO2019126041A1
(en)
|
2017-12-18 |
2019-06-27 |
The General Hospital Corporation |
Glycoengineering
|
AU2019210204A1
(en)
|
2018-01-18 |
2020-08-13 |
EndoProtech, Inc. |
Treating microvascular dysfunction
|
WO2019155387A1
(en)
|
2018-02-07 |
2019-08-15 |
St. Jude Children's Research Hospital |
Epigenetic histone regulation mediated by cxorf67
|
US11730774B2
(en)
|
2018-02-28 |
2023-08-22 |
The Johns Hopkins University |
Bacterial biofilms and cancer
|
WO2019173181A1
(en)
|
2018-03-05 |
2019-09-12 |
Amgen Inc. |
Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
|
EP3773505A4
(en)
|
2018-03-30 |
2021-12-22 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
US20190314324A1
(en)
|
2018-04-13 |
2019-10-17 |
The University Of Chicago |
Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
|
CN112424352A
(en)
|
2018-05-11 |
2021-02-26 |
阿尔法阿诺麦里克公司 |
Oligonucleotide conjugates comprising 7 '-5' -alpha-anomeric bicyclic sugar nucleosides
|
CN112533918A
(en)
|
2018-06-13 |
2021-03-19 |
安菲斯塔治疗有限责任公司 |
Bifunctional molecules for targeting Rpn11
|
WO2019238816A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting uchl5
|
WO2019238886A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting usp14
|
US20210230545A1
(en)
|
2018-07-09 |
2021-07-29 |
St. Jude Children's Research Hospital |
Use of il-12 to alter epigenetic effector programs in cd8 t cells
|
WO2020023806A1
(en)
|
2018-07-25 |
2020-01-30 |
The Johns Hopkins University |
Compositions and methods for generation of heart field-specific progenitor cells
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
US11938135B2
(en)
|
2018-10-16 |
2024-03-26 |
The Johns Hopkins University |
Compositions and methods for treating vascular Ehlers Danlos syndrome and associated disorders
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
US11931397B2
(en)
|
2018-12-06 |
2024-03-19 |
Stealth Biotherapeutics Inc. |
Methods and compositions for the treatment of Sengers syndrome
|
US20220136051A1
(en)
|
2019-02-22 |
2022-05-05 |
St. Jude Children's Research Hospital |
Methods for identifying and improving t cell multipotency
|
WO2020176863A1
(en)
|
2019-02-28 |
2020-09-03 |
Kezar Life Sciences |
Thiazole derivatives as protein secretion inhibitors
|
CN113905724A
(en)
|
2019-04-15 |
2022-01-07 |
儿童医学中心公司 |
Aerosolized compositions comprising mitochondria and methods of use thereof
|
GB2598520A
(en)
|
2019-05-28 |
2022-03-02 |
Univ Shanghai Tech |
Composition and methods to treat ectodermal dysplasia 2, Clouston type
|
JP2022542882A
(en)
|
2019-07-24 |
2022-10-07 |
ステルス バイオセラピューティクス インコーポレイテッド |
Peptidomimetic compounds (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxa) in the treatment of neurodegenerative diseases Diazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-I-oxopropan-2-yl)-5-guanidinopentanamide
|
WO2021067836A1
(en)
|
2019-10-04 |
2021-04-08 |
Stealth Biotherapeutics Corp |
Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
|
AU2020367532A1
(en)
|
2019-10-17 |
2022-05-12 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
|
CN115315273A
(en)
|
2020-01-14 |
2022-11-08 |
辛德凯因股份有限公司 |
IL-2 orthologs and methods of use thereof
|
EP4090674A4
(en)
|
2020-01-14 |
2024-01-24 |
Synthekine Inc |
Biased il2 muteins methods and compositions
|
TW202140550A
(en)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody
|
EP4126836A1
(en)
|
2020-04-03 |
2023-02-08 |
Stealth BioTherapeutics Inc. |
Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
|
CA3173673A1
(en)
|
2020-04-23 |
2021-10-28 |
The Regents Of The University Of California |
Genetically engineered phagocytes, and related compositions, vectors, methods and systems
|
US20230227555A1
(en)
|
2020-07-30 |
2023-07-20 |
Tiziana Life Sciences Plc |
Cd-3 antibodies for the treatment of coronavirus
|
CN116322754A
(en)
|
2020-08-05 |
2023-06-23 |
辛德凯因股份有限公司 |
IL10RA binding molecules and methods of use
|
WO2022031884A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rg binding molecules and methods of use
|
IL300736A
(en)
|
2020-08-31 |
2023-04-01 |
Kezar Life Sciences |
Protein secretion inhibitors
|
MX2023005201A
(en)
|
2020-11-04 |
2023-06-28 |
Myeloid Therapeutics Inc |
Engineered chimeric fusion protein compositions and methods of use thereof.
|
EP4251170A1
(en)
|
2020-11-25 |
2023-10-04 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
EP4291306A1
(en)
|
2021-02-09 |
2023-12-20 |
University of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
WO2023064942A1
(en)
|
2021-10-14 |
2023-04-20 |
Tiziana Life Sciences Plc |
Methods of suppressing microglial activation
|
WO2023069255A1
(en)
|
2021-10-20 |
2023-04-27 |
Stealth Biotherapeutics Inc. |
Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
|
WO2023101963A2
(en)
|
2021-11-30 |
2023-06-08 |
Northwestern University |
Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
|
WO2023133321A1
(en)
|
2022-01-10 |
2023-07-13 |
Stealth Biotherapeutics Inc. |
Small molecule peptidomimetic for the treatment of tauopathies
|
WO2023164250A1
(en)
|
2022-02-28 |
2023-08-31 |
Kezar Life Sciences |
Sec61 inhibitors and use thereof
|
WO2023198757A1
(en)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
|
GB202214445D0
(en)
*
|
2022-09-30 |
2022-11-16 |
Imp College Innovations Ltd |
Gene therapy
|